Esteve Pharmaceuticals, S.A.
Esteve, officially known as Esteve Pharmaceuticals, is a prominent player in the pharmaceutical industry, headquartered in Barcelona, Spain. Founded in 1929, Esteve has established a strong presence in various operational regions, including Europe and Latin America, focusing on innovative healthcare solutions. The company is renowned for its expertise in the development of prescription medicines, particularly in pain management, respiratory diseases, and central nervous system disorders. Esteve's commitment to research and development has led to the creation of unique products that address unmet medical needs, positioning it as a trusted name in the pharmaceutical sector. With a rich history marked by significant milestones, Esteve continues to achieve notable recognition for its contributions to healthcare, maintaining a competitive edge through its dedication to quality and innovation.
DitchCarbon Score
How does Esteve Pharmaceuticals, S.A.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Esteve Pharmaceuticals, S.A.'s score of 33 is higher than 88% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Esteve Pharmaceuticals, S.A.'s reported carbon emissions
In 2023, Esteve reported total carbon emissions of approximately 290,716,000 kg CO2e. This figure includes 115,001,000 kg CO2e from Scope 1 emissions, 177,000 kg CO2e from Scope 2 emissions, and 279,038,000 kg CO2e from Scope 3 emissions. Comparatively, in 2022, Esteve's total emissions were about 306,707,000 kg CO2e, indicating a slight reduction in emissions year-on-year. The breakdown for 2022 included 9,553,000 kg CO2e from Scope 1, 15,672,000 kg CO2e from Scope 2, and 281,482,000 kg CO2e from Scope 3. Despite these figures, Esteve has not publicly committed to specific reduction targets or initiatives, as there are no documented reduction targets or climate pledges available. The company continues to disclose emissions across all three scopes, demonstrating transparency in its environmental impact reporting.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2009 | 2010 | 2011 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 9,982,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 000,000,000 |
| Scope 2 | 16,014,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 000,000 |
| Scope 3 | 11,963,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Esteve Pharmaceuticals, S.A. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
